Analysts Set Harpoon Therapeutics, Inc. (NASDAQ:HARP) Price Target at $27.25

Shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP) have received a consensus recommendation of “Hold” from the six brokerages that are currently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $27.25.

Several equities analysts recently commented on the stock. Oppenheimer restated an “outperform” rating on shares of Harpoon Therapeutics in a research note on Tuesday, March 26th. Citigroup reiterated a “neutral” rating and set a $23.00 price objective (up from $13.00) on shares of Harpoon Therapeutics in a research note on Monday, February 26th. HC Wainwright downgraded shares of Harpoon Therapeutics from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $12.00 to $23.00 in a research note on Monday, January 8th. Leerink Partnrs downgraded shares of Harpoon Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, January 8th. Finally, TD Cowen reiterated a “market perform” rating on shares of Harpoon Therapeutics in a research note on Tuesday, January 16th.

Harpoon Therapeutics Stock Performance

HARP stock opened at $23.01 on Friday. The company’s 50-day simple moving average is $22.86 and its 200 day simple moving average is $15.43. Harpoon Therapeutics has a 52 week low of $3.11 and a 52 week high of $23.21. The company has a market capitalization of $389.61 million, a PE ratio of -2.63 and a beta of 2.11.

Insider Transactions at Harpoon Therapeutics

In other Harpoon Therapeutics news, major shareholder Merck & Co., Inc. acquired 21,397,205 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was acquired at an average price of $23.00 per share, for a total transaction of $492,135,715.00. Following the acquisition, the insider now directly owns 1,000 shares in the company, valued at $23,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 17.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in HARP. BNP Paribas Arbitrage SA grew its position in shares of Harpoon Therapeutics by 571.5% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 12,986 shares of the company’s stock worth $25,000 after buying an additional 11,052 shares during the period. Prudential Financial Inc. acquired a new stake in shares of Harpoon Therapeutics during the 1st quarter worth approximately $32,000. Two Sigma Investments LP grew its position in shares of Harpoon Therapeutics by 73.6% during the 3rd quarter. Two Sigma Investments LP now owns 33,361 shares of the company’s stock worth $32,000 after buying an additional 14,149 shares during the period. Susquehanna International Group LLP grew its position in shares of Harpoon Therapeutics by 168.1% during the 1st quarter. Susquehanna International Group LLP now owns 53,949 shares of the company’s stock worth $40,000 after buying an additional 33,830 shares during the period. Finally, Sequoia Financial Advisors LLC acquired a new stake in shares of Harpoon Therapeutics during the 4th quarter worth approximately $44,000. Institutional investors own 74.01% of the company’s stock.

Harpoon Therapeutics Company Profile

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma.